The bioanalysis of endogenous biomarkers requires a broad range of expertise. Biomarker molecules vary extensively with respect to concentrations that need to be quantified, the biomarker class and its chemical characteristics, as well as the levels already present in the sample matrix.
In the case of biomarker analysis the context-of-use of the analytical data is key in developing a method that is fit for the purpose. Another challenge could be that a reference material is not available for that particular biomarker analyte.
Lablytica supports Elypta in the development of their metabolism-based liquid biopsy platform.